Trial Profile

Phase I/II Study of Expanded, Activated Autologous Natural Killer Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary) ; Bevacizumab; Interleukin-2; Natural killer cell therapy
Indications Advanced breast cancer; Gastric cancer
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

04 Jun 2019 Status changed to completed, according to results published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO 2019).
04 Jun 2019 Results of phase I and phase Ib portion of study assessing efficacy and safety published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO 2019).
04 Jun 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com